title: Treatment of localized prostatic carcinoma using the transrectal ultrasound guided transperineal implantation technique.
abstract: Treatment of localized prostate cancer by ultrasonically guided transperineal 125I implantation, in contrast to open 125I implantation, may allow for ideal distribution of the seeds and may therefore lead to better treatment results. 46 patients with localized prostatic carcinoma (T1-T2, G1-G3, N0, M0) have been treated since 1985, using this new technique. The longest follow-up is 64 months (median 30 months). The irradiation implantation dose to the prostate was 160 Gy. Assessed by ultrasonography an average prostate volume reduction of 20% was achieved at 6 months, increasing to 24% at 12 months, 39% at 24 months and 56% at 48 months. To evaluate response of the primary tumor systematic ultrasonically guided needle biopsies from the previous malignant prostate areas were performed in all patients every 6 months during follow-up. Tumor-negative biopsies were obtained in 33% of patients at 12 months, 40% at 24 months, progressively increasing to 50% at 48 months. Three patients developed distant metastases, and 6 died, of whom 1 patient due to prostate cancer. Morbidity from implantation has been low and the erectile function was preserved in all patients at 12 months postimplantation. The high percentage of tumor-positive biopsies during follow-up indicates that this technique fails to cure a significant proportion of patients.
authors.affiliation: Department of Urology, University of Amsterdam, The Netherlands.
authors.forename: P L
authors.initials: PL
authors.lastname: Vijverberg
authors.forename: K H
authors.initials: KH
authors.lastname: Kurth
authors.forename: L E
authors.initials: LE
authors.lastname: Blank
authors.forename: N F
authors.initials: NF
authors.lastname: Dabhoiwala
authors.forename: T H
authors.initials: TH
authors.lastname: de Reijke
authors.forename: K
authors.initials: K
authors.lastname: Koedooder
mesh_terms: D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D009017:Morbidity; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000532:radiotherapy*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography / Q000379:methods*
chemical_list: D007457:Iodine Radioisotopes